Abnormality Prevalence* MetS component (not segregated) COB Hyper-GL HBP Low-HDL Hyper-TG MetS component (segregated by count and combination) Single component Hyper-GL alone Low-HDL alone HBP alone Hyper-TG alone COB alone Two components Low-HDL-plus-Hyper-TG Hyper-GL-plus-Low-HDL Low-HDL-plus-HBP Hyper-TG-plus-HBP Hyper-GL-plus-Hyper-TG COB-plus-Low-HDL COB-plus-HBP COB-plus-Hyper-GL COB-plus-Hyper-TG Overall N = 1384 54 (3.9%) 284 (20.5%) 245 (17.7%) 338 (24.4%) 190 (13.7%) 511 (36.9%) 149 (10.8%) 168 (12.1%) 115 (8.3%) 63 (4.6%) 16 (1.2%) 300 (21.7%) 61 (4.4%) 51 (3.7%) 42 (3.0%) 31 (2.2%) 30 (2.2%) 16 (1.2%) 10 (0.7%) 7 (0.5%) 5 (0.4%) 28 (2.3%) 234 (19.4%) 193 (16.0%) 269 (22.2%) 139 (11.5%) 451 (37.3%) 132 (10.9%) 151 (12.5%) 107 (8.9%) 51 (4.2%) 10 (0.8%) 206 (17.0%) 43 (3.6%) 42 (3.5%) 26 (2.2%) 22 (1.8%) 22 (1.8%) 7 (0.6%) 5 (0.4%) 5 (0.4%) 1 (0.1%) Lin et al. BMC Public Health 2010, 10:747 http://www.biomedcentral.com/1471-2458/10/747 Page 5 of 8 Table 2 Baseline prevalence rates for Taiwanese adult workers not fulfilling metabolic syndrome (MetS) criteria initially 2002 baseline data, divided by MetS outcome in 2007** Without MetS outcome n = 1209 With MetS outcome, n = 175 * The abnormality prevalence is demonstrated as numbers and proportions, %. The upper rows are non-segregated distributions of MetS components, one or two risk factors are included and overlapping can happen; the lower rows are segregated by each signal and combinations, all individual conditions are listed. Abbreviations: Hyper-GL, hyperglycemia; Low-HDL, Low-HDL cholesterolemia; HBP, high blood pressure; Hyper-TG, hypertriglyceridemia; COB, central obesity. **c2 tests were conducted for categorical variables between groups with/without MetS outcome. Table 3 Model 1, adjusted risks for metabolic syndrome (MetS), conventionally, individual MetS-components are not separated apart Baseline potential risk factors* Adjusted-OR** 95%CI p MetS component COB 7.5 4.0 – 14.2 <0.01 Hyper-TG 2.4 1.5 – 3.7 <0.01 Hyper-GL 2.2 1.4 – 3.3 <0.01 Low-HDL 2.7 1.8 – 4.0 <0.01 HBP 2.5 1.6 – 3.9 <0.01 Hyperuricemia 1.0 0.6 – 1.6 0.98 Sonographic fatty liver 2.3 1.6 – 3.5 <0.01 Elevated alanine aminotransferase 1.3 0.8 – 2.1 0.36 Elevated g-glutamil transferase 2.0 1.3 – 3.1 <0.01 Hyperinsulinemia 1.7 1.1 – 2.6 <0.01 * Abbreviations: Hyper-GL, hyperglycemia; Low-HDL, Low-HDL cholesterolemia; HBP, High blood pressure; Hyper-TG, hypertriglyceridemia; COB, central obesity ** Adjusted variables were age and categorical variables including gender, smoking, diet habits, drinking, exercise status, sonographic liver enzymes, fatty liver, hepatovirus infections, hyperinsulinemia and hyperuricemia. Table 4 Model 2, adjusted risks for metabolic syndrome (MetS) using MetS-component count as potential risk factors Baseline potential risk factors Adjusted-OR* 95%CI p MetS component count Adults having a single MetS 2.8 1.6 – 4.7 <0.01 component Adults having two MetS 7.3 4.3 – 12.6 <0.01 components Hyperuricemia 1.0 0.6 – 1.6 0.99 Sonographic fatty liver 2.4 1.6 – 3.6 <0.01 Elevated alanine aminotransferase 1.3 0.8 – 2.1 0.37 Elevated g-glutamyl transferase 2.0 1.2 – 3.1 <0.01 Hyperinsulinemia 1.8 1.2 – 2.6 <0.01 * Adjusted variables were age and categorical variables including gender, smoking, diet habits, drinking, exercise status, liver enzymes, sonographic fatty liver, hepatovirus infections, hyperinsulinemia and hyperuricemia. 26(14.9%) 50(28.6%) 52(29.7%) 69(39.4%) 51(29.1%) 60 (34.3%) 17(9.7%) 17(9.7%) 8(4.6%) 12(6.9%) 6(3.4%) 94 (53.7%) 18(10.3%) 9(5.1%) 16(9.1%) 9(5.1%) 8(4.6%) 9(5.1%) 5(2.9%) 2(1.1%) 4(2.3%) P <0.01 0.01 <0.01 <0.01 <0.01 0.44 0.62 0.27 0.02 0.19 0.07 <0.01 <0.01 0.34 <0.01 0.05 0.09 <0.01 0.06 0.38 0.05